IL6 and prostate carcinoma: The comparison of prostate cancer cell lines LnCaP, DU145 and PC3 sensitivity for selective conjugates 2, 4, 5 and 8 based on the results from cytotoxicity tests (MTT and LDH), apoptosis assay and IL-6 release inhibition.